EA201200855A1 - Модуляторы crth2 - Google Patents
Модуляторы crth2Info
- Publication number
- EA201200855A1 EA201200855A1 EA201200855A EA201200855A EA201200855A1 EA 201200855 A1 EA201200855 A1 EA 201200855A1 EA 201200855 A EA201200855 A EA 201200855A EA 201200855 A EA201200855 A EA 201200855A EA 201200855 A1 EA201200855 A1 EA 201200855A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crth2
- modulators
- crth2 modulators
- treatment
- general formula
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title abstract 3
- 108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
Abstract
Изобретение описывает модуляторы CRTH2 и особенно антагонисты CRTH2, пригодные для лечения различных заболеваний, включая астму и респираторные расстройства. Описанные соединения соответствуют общей формуле (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28984109P | 2009-12-23 | 2009-12-23 | |
PCT/US2010/060671 WO2011079007A1 (en) | 2009-12-23 | 2010-12-16 | Crth2 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201200855A1 true EA201200855A1 (ru) | 2013-04-30 |
Family
ID=43735997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200855A EA201200855A1 (ru) | 2009-12-23 | 2010-12-16 | Модуляторы crth2 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8674115B2 (ru) |
EP (1) | EP2516416A1 (ru) |
JP (1) | JP5731538B2 (ru) |
KR (1) | KR20120098908A (ru) |
CN (1) | CN102822163B (ru) |
AR (1) | AR079492A1 (ru) |
AU (1) | AU2010333829A1 (ru) |
BR (1) | BR112012017756A2 (ru) |
CA (1) | CA2785191A1 (ru) |
CL (1) | CL2012001712A1 (ru) |
CO (1) | CO6640201A2 (ru) |
CR (1) | CR20120343A (ru) |
EA (1) | EA201200855A1 (ru) |
EC (1) | ECSP12011996A (ru) |
MX (1) | MX2012007239A (ru) |
SG (1) | SG181900A1 (ru) |
TW (1) | TW201130810A (ru) |
UY (1) | UY33110A (ru) |
WO (1) | WO2011079007A1 (ru) |
ZA (1) | ZA201204527B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140187795A1 (en) * | 2010-12-08 | 2014-07-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators and preparation thereof |
EP2688882B1 (en) * | 2011-03-25 | 2015-05-13 | Boehringer Ingelheim International GmbH | Pyrazole compounds as crth2 antagonists |
WO2013155422A1 (en) * | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
WO2017104728A1 (ja) * | 2015-12-16 | 2017-06-22 | 国立大学法人東京大学 | 食物アレルギー治療薬 |
JP6894449B2 (ja) | 2016-04-22 | 2021-06-30 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 癌を治療するためのマクロ環状mcl1阻害剤 |
US20230192631A1 (en) * | 2020-04-16 | 2023-06-22 | Hoffmann-La Roche Inc. | Biphenyl Derivatives |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
MX9205392A (es) * | 1991-10-29 | 1993-04-01 | Du Pont | Triazolcarbozamidas herbicidas y procedimiento para su obtencion. |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
AU714312B2 (en) | 1995-06-21 | 1999-12-23 | Shionogi & Co., Ltd. | Bicyclic amino derivatives and PGD2 antagonist containing them |
US5859042A (en) * | 1995-09-27 | 1999-01-12 | Ono Pharmaceutical Co., Ltd. | Five membered heterocyclic compounds |
JP4120993B2 (ja) | 1996-12-12 | 2008-07-16 | 塩野義製薬株式会社 | ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するpgd2拮抗剤 |
CN1105112C (zh) | 1996-12-13 | 2003-04-09 | 盐野义制药株式会社 | 苯并噻吩酰胺类衍生物以及含有它们的pgd2拮抗剂 |
DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
JP2003530426A (ja) | 2000-04-12 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | Pgd2受容体拮抗薬を用いるアレルギー状態の治療のための方法および組成物 |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
ATE456559T1 (de) | 2001-10-22 | 2010-02-15 | Pfizer Prod Inc | Piperazinderivate mit ccr1-rezeptor- antagonistischer wirkung |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
RS51550B (en) | 2002-04-08 | 2011-06-30 | Pfizer Inc. | KAO DERIVATIVES KAO MODULATORS CCR5 |
AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
WO2004014875A1 (en) | 2002-08-12 | 2004-02-19 | Pfizer Products Inc. | Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide |
SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
DE60318219T2 (de) | 2002-08-24 | 2009-01-15 | Astrazeneca Ab | PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
JP2006508077A (ja) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのpgd2レセプタアンタゴニスト |
US20040116441A1 (en) | 2002-10-30 | 2004-06-17 | Pfizer Inc | Methods of using sulfonic acid derivatives |
US20040092529A1 (en) | 2002-10-30 | 2004-05-13 | Pfizer Inc | Methods of using piperazine derivatives |
US20040097554A1 (en) | 2002-10-30 | 2004-05-20 | Pfizer Inc | Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents |
SE0203820D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
US7321001B2 (en) | 2002-12-20 | 2008-01-22 | Amgen Inc. | Asthma and allergic inflammation modulators |
SE0203828D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Chemical compounds |
AR042628A1 (es) | 2002-12-20 | 2005-06-29 | Astrazeneca Ab | Derivados de piperidina como moduladores del receptor ccr5 |
MXPA06001506A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa. |
US8022063B2 (en) * | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
CN1980908A (zh) | 2004-05-29 | 2007-06-13 | 7Tm制药联合股份有限公司 | 取代的噻唑乙酸作为crth2配体 |
WO2005116001A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Substituted thiazoleacetic as crth2 ligands |
EP1758571A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for therapeutic use |
GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
PL2046740T3 (pl) * | 2006-07-22 | 2012-10-31 | Oxagen Ltd | Związki o aktywności antagonisty CRTH2 |
JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
EP2268281A4 (en) * | 2008-02-15 | 2012-05-02 | Abbott Lab | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS |
-
2010
- 2010-12-16 WO PCT/US2010/060671 patent/WO2011079007A1/en active Application Filing
- 2010-12-16 EP EP10798887A patent/EP2516416A1/en not_active Withdrawn
- 2010-12-16 TW TW099144402A patent/TW201130810A/zh unknown
- 2010-12-16 AU AU2010333829A patent/AU2010333829A1/en not_active Abandoned
- 2010-12-16 UY UY33110A patent/UY33110A/es not_active Application Discontinuation
- 2010-12-16 MX MX2012007239A patent/MX2012007239A/es active IP Right Grant
- 2010-12-16 KR KR1020127019130A patent/KR20120098908A/ko not_active Application Discontinuation
- 2010-12-16 JP JP2012546053A patent/JP5731538B2/ja not_active Expired - Fee Related
- 2010-12-16 CN CN201080059094.XA patent/CN102822163B/zh not_active Expired - Fee Related
- 2010-12-16 EA EA201200855A patent/EA201200855A1/ru unknown
- 2010-12-16 SG SG2012046678A patent/SG181900A1/en unknown
- 2010-12-16 BR BR112012017756A patent/BR112012017756A2/pt not_active Application Discontinuation
- 2010-12-16 AR ARP100104664A patent/AR079492A1/es not_active Application Discontinuation
- 2010-12-16 CA CA2785191A patent/CA2785191A1/en not_active Abandoned
- 2010-12-16 US US12/969,840 patent/US8674115B2/en active Active
-
2012
- 2012-06-19 ZA ZA2012/04527A patent/ZA201204527B/en unknown
- 2012-06-22 CO CO12105121A patent/CO6640201A2/es not_active Application Discontinuation
- 2012-06-22 CL CL2012001712A patent/CL2012001712A1/es unknown
- 2012-06-22 EC ECSP12011996 patent/ECSP12011996A/es unknown
- 2012-06-22 CR CR20120343A patent/CR20120343A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP12011996A (es) | 2012-10-30 |
BR112012017756A2 (pt) | 2016-04-19 |
CL2012001712A1 (es) | 2012-12-07 |
CA2785191A1 (en) | 2011-06-30 |
US20110150834A1 (en) | 2011-06-23 |
WO2011079007A1 (en) | 2011-06-30 |
AR079492A1 (es) | 2012-02-01 |
JP2013515726A (ja) | 2013-05-09 |
SG181900A1 (en) | 2012-08-30 |
AU2010333829A1 (en) | 2012-07-12 |
CN102822163B (zh) | 2016-01-20 |
ZA201204527B (en) | 2013-09-25 |
MX2012007239A (es) | 2012-10-15 |
US8674115B2 (en) | 2014-03-18 |
TW201130810A (en) | 2011-09-16 |
KR20120098908A (ko) | 2012-09-05 |
UY33110A (es) | 2011-07-29 |
CR20120343A (es) | 2013-01-25 |
EP2516416A1 (en) | 2012-10-31 |
JP5731538B2 (ja) | 2015-06-10 |
CN102822163A (zh) | 2012-12-12 |
CO6640201A2 (es) | 2013-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
EA020330B3 (ru) | Хиназолиновые соединения | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
EA201101182A1 (ru) | Новые аминоазагетероциклические карбоксамиды | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
EA201171081A1 (ru) | Производные индола в качестве антагонистов рецептора crth2 | |
MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
BR112015029970A2 (pt) | inibidores de cinase | |
ATE541832T1 (de) | Neuartige p2x7r-antagonisten und ihre verwendung | |
MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
EA201500403A1 (ru) | Соединения, активирующие теломеразу, и способы их применения | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos |